Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6214MR)

This product GTTS-WQ6214MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6214MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4771MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ10016MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ5164MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ4003MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ5155MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ9492MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ7041MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ361MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW